![Mark Geyer: Tigen Pharma has formally agreed to partner with us in clinical development of our CAR T-cell product for AML](https://oncodaily.com/pub/uploads/2024/01/geyer-mark_210805_027_1200x800-1.png)
Photo of Mark Geyer taken from www.mskcc.org
Feb 2, 2024, 05:57
Mark Geyer: Tigen Pharma has formally agreed to partner with us in clinical development of our CAR T-cell product for AML
Mark Geyer, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, recently shared on X/Twitter:
“Thrilled that Tigen Pharma has formally agreed to partner with us in clinical development of our CD371-targeted IL-18 secreting CAR T-cell product for AML, currently in a phase I study I’m leading at Memorial Sloan Kettering Cancer Center with plans to expand.”
Source: Mark Geyer/X